Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BAFIERTAM vs BAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
FDA-approved: Treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.,Off-label: None widely documented.
Arsenic poisoning,Mercury poisoning,Lead poisoning (adjunct to edetate calcium disodium),Acute gold poisoning,Wilson's disease (investigational)
120 mg orally once daily.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
Approximately 12 hours (range 8–15 hours); permits twice-daily dosing in multiple sclerosis.
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
BAFIERTAM is a prodrug that is rapidly metabolized by esterases in the gastrointestinal tract, blood, and tissues to monomethyl fumarate. Monomethyl fumarate is further metabolized via the tricarboxylic acid (TCA) cycle, with no significant involvement of cytochrome P450 enzymes.
Primarily hepatic; undergoes oxidation and conjugation; metabolites excreted renally.
Primarily via renal excretion as unchanged drug (approximately 80% of the dose); minimal biliary/fecal elimination (<5%).
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
30–40% bound to plasma proteins, primarily albumin.
BAL is extensively bound to plasma proteins, primarily albumin, with protein binding >90%.
Approximately 0.5–0.7 L/kg; indicates distribution into total body water with limited tissue binding.
Volume of distribution is approximately 3.5 L/kg, indicating extensive distribution into tissues, including brain and intracellular spaces.
Oral: Approximately 50% (due to first-pass metabolism); administer with food to reduce GI irritation.
BAL is not administered orally due to poor absorption and gastrointestinal irritation. Given intravenously, bioavailability is 100%. Intramuscular bioavailability is similar but with slower absorption.
No dose adjustment required for GFR ≥30 m L/min. Not recommended for GFR <30 m L/min.
GFR 10-50 m L/min: reduce frequency to every 6-8 hours; GFR <10 m L/min: reduce frequency to every 8-12 hours.
Use with caution in hepatic impairment; reduce dose to 60 mg once daily in Child-Pugh Class B or C.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: reduce dose by 50% and monitor for hepatotoxicity.
Not established in pediatric patients.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days; maximum 100 mg per dose.
No specific dose adjustment; use with caution due to age-related decline in renal function.
Start at 3 mg/kg IM every 6 hours; adjust based on renal function, monitor for hypotension and pain at injection site.
No black box warning.
None.
Lymphopenia: May cause reduction in lymphocyte counts; monitor complete blood count before and periodically during treatment.,Hypersensitivity reactions: Anaphylaxis and angioedema may occur; discontinue if severe.,Progressive multifocal leukoencephalopathy (PML): Reported in patients with prolonged lymphopenia; consider holding therapy if lymphocyte counts drop below 0.2 x 10^9/L.,Hepatic injury: Elevations of liver enzymes have been reported; monitor in patients with pre-existing liver disease.,Flushing and gastrointestinal events: Common; may be managed by taking with food or using aspirin.
Monitor renal function and serum electrolytes during therapy.,Can cause hypertension, tachycardia, and myocardial ischemia; use cautiously in cardiovascular disease.,May induce hemolytic anemia in patients with G6PD deficiency.,Injection site reactions and sterile abscesses may occur.,Iron deficiency is a known adverse effect due to iron chelation.
Known hypersensitivity to BAFIERTAM, monomethyl fumarate, or any excipient.,Concomitant use with dimethyl fumarate or other fumaric acid esters.
Hypersensitivity to BAL or any component.,Hepatic insufficiency (unless benefit outweighs risk).,Iron poisoning (forms toxic complex).,Concurrent use with cadmium or selenium (increased toxicity).
Administer with food to reduce flushing and gastrointestinal adverse effects. Avoid alcohol consumption during treatment as it may exacerbate flushing. No specific dietary restrictions are required.
Avoid alcohol and caffeine. Maintain adequate hydration. No specific food restrictions, but ensure iron-rich foods are avoided if concurrent iron poisoning suspected (though BAL not indicated for iron).
BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic potential.
Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.
No data on presence in human milk. M/P ratio unknown. Risk of infant exposure cannot be excluded. Discontinue breastfeeding or drug, considering importance to mother.
BAL (dimercaprol) is excreted into breast milk; M/P ratio unknown. Limited data; exercise caution and consider temporary cessation of breastfeeding during therapy.
No dose adjustment data; contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately. Pharmacokinetic changes unknown but drug should not be used.
No specific dose adjustments recommended in pregnancy; monitor for increased volume of distribution and potential need for higher doses if toxicity persists.
BAFIERTAM (monomethyl fumarate) is a prodrug of monomethyl fumarate, indicated for relapsing forms of multiple sclerosis. Administer with food to reduce flushing and gastrointestinal adverse effects. Titrate as per recommended schedule to improve tolerability. Monitor complete blood count, liver function tests, and renal function at baseline and periodically. Flushing may be reduced by taking with food or using non-enteric coated aspirin (325 mg) 30 minutes prior. Avoid concurrent use with dimethyl fumarate or other fumaric acid esters.
BAL (dimercaprol) is used as a chelating agent for heavy metal poisoning, particularly arsenic, lead, and mercury. Administer deep IM only; avoid IV due to risk of hemolysis. Monitor blood pressure closely as hypertension can occur. Contraindicated in peanut allergy due to peanut oil vehicle. Administer with alkaline urine to protect kidneys.
Take BAFIERTAM exactly as prescribed, usually twice daily with food.,Flushing and gastrointestinal upset are common but may decrease over time; taking with food and gradual dose titration helps.,Do not crush, chew, or open capsules; swallow whole.,Report any signs of infection, unusual bruising or bleeding, or severe abdominal pain to your healthcare provider.,Avoid consuming alcohol, as it may increase flushing risk.,If you miss a dose, take it as soon as you remember unless it is near the time of the next dose; do not double up.,Inform all healthcare providers that you are taking BAFIERTAM.
This medication is given as an injection into a muscle.,You may experience a metallic taste, headache, or nausea.,Report any signs of allergic reaction such as rash or difficulty breathing.,Avoid alcohol while on this medication.,Do not drive or operate heavy machinery until you know how this drug affects you.
No interactions on record
"Pregabalin, a gabapentinoid, enhances the inhibitory effects of GABA by binding to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. Dapiprazole, an α1-adrenoceptor antagonist used for miosis, can have its therapeutic efficacy increased when combined with pregabalin due to additive central nervous system depression. This interaction may result in enhanced sedation, dizziness, and psychomotor impairment, potentially increasing the risk of falls and cognitive dysfunction."
"Pregabalin and pravastatin may exhibit an additive risk of musculoskeletal adverse effects, particularly myopathy and rhabdomyolysis, due to their overlapping effects on muscle cells. Pregabalin can cause dose-related muscle damage, while pravastatin inhibits HMG-CoA reductase, leading to reduced skeletal muscle integrity. This combination may potentiate serum creatine kinase elevations and increase the likelihood of clinical myopathy, especially in patients with predisposing factors such as renal impairment or concomitant use of other myotoxic agents."
"Pregabalin may cause fluid retention and peripheral edema, which can precipitate or exacerbate heart failure, especially in patients with pre-existing cardiac risk factors. Rosiglitazone, a thiazolidinedione, also promotes fluid retention and increases plasma volume via PPAR-γ-mediated renal effects. When combined, the additive fluid-retaining properties of both drugs can synergistically elevate the risk of new-onset or worsening heart failure, particularly in patients with reduced left ventricular function or NYHA Class III/IV status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BAFIERTAM vs BAL, answered by our medical review team.
BAFIERTAM is a Iron Chelating Agent that works by BAFIERTAM (monomethyl fumarate) is a prodrug that is rapidly hydrolyzed to monomethyl fumarate, which activates the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, leading to upregulation of antioxidant response elements and cytoprotective proteins. It also modulates immune responses by shifting from a pro-inflammatory to an anti-inflammatory state.. BAL is a Chelating Agent that works by Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BAFIERTAM and BAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BAFIERTAM is: 120 mg orally once daily.. The standard adult dose of BAL is: 3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BAFIERTAM and BAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BAFIERTAM is classified as Category C. BAFIERTAM (monomethyl fumarate) is contraindicated in pregnancy. Animal studies show malformations at subclinical doses. No human data; avoid in all trimesters due to teratogenic p. BAL is classified as Category C. Insufficient human data; animal studies suggest potential teratogenicity at high doses. Avoid in first trimester unless benefit outweighs risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.